IP Library › Granted Patent US 12,715,862
Granted Patent B2
US 12,715,862 · App. 18/258,351 · Granted Aug 25, 2026

Antagonists of the muscarinic acetylcholine receptor M4

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,715,862
App. No.
18/258,351
Filed
Jun 20, 2023
Granted
Aug 25, 2026
Kind
B2
Art Unit
1629
USPC
514/252.03
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2023
From: BENDER, AARON M.; SPOCK, MATTHEW; KORKMAZ-VAISYS, MELISSA A.; MALINKY, CORI A.; CONN, P. JEFFREY; LINDSLEY, CRAIG W.
To: VANDERBILT UNIVERSITY
Reel/Frame 063993/0856 →
Continuity (5)
Provisional Application 63284750 · Dec 1, 2021
Provisional Application 63208877 · Jun 9, 2021
Provisional Application 63170899 · Apr 5, 2021
Provisional Application 63129196 · Dec 22, 2020
Related Publication 20240109873A1 · Apr 4, 2024
References Cited (189)
US 5221675A · Chung et al. · 1993 [cited by applicant]
US 5726172A · Sparks et al. · 1998 [cited by applicant]
US 6890936B2 · Boyle et al. · 2005 [cited by applicant]
US 7517905B2 · Mehta et al. · 2009 [cited by applicant]
US 7560551B2 · Cee et al. · 2009 [cited by applicant]
US 7745449B2 · Hong et al. · 2010 [cited by applicant]
US 7932246B2 · Moffat et al. · 2011 [cited by applicant]
US 8173667B2 · Feuerbach et al. · 2012 [cited by applicant]
US 8178575B2 · Tang et al. · 2012 [cited by applicant]
US 8691865B2 · Searle et al. · 2014 [cited by applicant]
US 9695151B2 · Aebi et al. · 2017 [cited by applicant]
US 9695152B2 · Aebi et al. · 2017 [cited by applicant]
US 10287267B2 · KC et al. · 2019 [cited by applicant]
US 11149022B2 · Lindsley et al. · 2021 [cited by applicant]
US 11225484B2 · Lindsley et al. · 2022 [cited by applicant]
US 11299481B2 · Lindsley et al. · 2022 [cited by applicant]
US 11299484B2 · Martin et al. · 2022 [cited by applicant]
US 11325896B2 · Lindsley et al. · 2022 [cited by applicant]
US 11352344B2 · Lindsley et al. · 2022 [cited by applicant]
US 11414406B2 · Lindsley et al. · 2022 [cited by applicant]
US 11820757B2 · Lindsley · 2023 [cited by examiner]
US 12319701B2 · Lindsley et al. · 2025 [cited by applicant]
US 12516067B2 · Bender et al. · 2026 [cited by applicant]
US 20040044029A1 · Dart et al. · 2004 [cited by applicant]
US 20040167224A1 · Ozaki et al. · 2004 [cited by applicant]
US 20060281805A1 · Mehta et al. · 2006 [cited by applicant]
US 20080146569A1 · Blake et al. · 2008 [cited by applicant]
US 20090176856A1 · Mehta et al. · 2009 [cited by applicant]
US 20090197860A1 · Ji et al. · 2009 [cited by applicant]
US 20090258872A1 · Schwink et al. · 2009 [cited by applicant]
US 20110281870A1 · Searle et al. · 2011 [cited by applicant]
US 20120129830A1 · Abouabdellah et al. · 2012 [cited by applicant]
US 20120157410A1 · Watterson et al. · 2012 [cited by applicant]
US 20120208820A1 · Schrimpf et al. · 2012 [cited by applicant]
US 20130225624A1 · Fisher et al. · 2013 [cited by applicant]
US 20140275011A1 · Mastracchio et al. · 2014 [cited by applicant]
US 20140364409A1 · Lindsley et al. · 2014 [cited by applicant]
US 20150284405A1 · Trzupek et al. · 2015 [cited by applicant]
US 20160332968A1 · Chobanian et al. · 2016 [cited by applicant]
US 20170015665A1 · Griffioen et al. · 2017 [cited by applicant]
US 20170037025A1 · Brown et al. · 2017 [cited by applicant]
US 20170044171A1 · Zhang et al. · 2017 [cited by applicant]
US 20170145020A1 · Zak et al. · 2017 [cited by applicant]
US 20170355678A1 · Bannen et al. · 2017 [cited by applicant]
US 20170355708A1 · Jefson et al. · 2017 [cited by applicant]
US 20180312471A1 · Xie et al. · 2018 [cited by applicant]
US 20190185461A1 · Wei et al. · 2019 [cited by applicant]
US 20200339547A1 · Lindsley et al. · 2020 [cited by applicant]
US 20200369650A1 · Lindsley et al. · 2020 [cited by applicant]
US 20200369666A1 · Lindsley et al. · 2020 [cited by applicant]
US 20200392117A1 · Lindsley et al. · 2020 [cited by applicant]
US 20210188811A1 · Lindsley et al. · 2021 [cited by applicant]
US 20210188820A1 · Lindsley et al. · 2021 [cited by applicant]
US 20220048913A1 · Lindsley et al. · 2022 [cited by applicant]
US 20220213069A1 · Lindsley et al. · 2022 [cited by applicant]
US 20230122344A1 · Lindsley · 2023 [cited by examiner]
US 20230150986A1 · Lindsley · 2023 [cited by examiner]
US 20230183218A1 · Lindsley · 2023 [cited by examiner]
US 20230183219A1 · Lindsley · 2023 [cited by examiner]
US 20230322799A1 · Bender et al. · 2023 [cited by applicant]
US 20240010640A1 · Bender · 2024 [cited by examiner]
US 20240083907A1 · Lindsley et al. · 2024 [cited by applicant]
US 20240116902A1 · Lindsley · 2024 [cited by examiner]
US 20240174655A1 · Bender et al. · 2024 [cited by applicant]
US 20240228468A1 · Bender · 2024 [cited by examiner]
US 20240287050A1 · Bender et al. · 2024 [cited by applicant]
US 20250145595A1 · Bender · 2025 [cited by examiner]
CN 101268071A · 2008 [cited by applicant]
CN 103102352A · 2013 [cited by applicant]
CN 106459039A · 2017 [cited by applicant]
CN 109310668A · 2019 [cited by applicant]
JP 2012107001A · 2012 [cited by applicant]
WO WO0011001A1 · 2000 [cited by applicant]
WO WO03091220A1 · 2003 [cited by applicant]
WO WO2004006846A2 · 2004 [cited by applicant]
WO WO2004056811A1 · 2004 [cited by applicant]
WO WO2004089898A1 · 2004 [cited by applicant]
WO WO2005030140A2 · 2005 [cited by applicant]
WO WO2005103003A2 · 2005 [cited by applicant]
WO WO2006035280A1 · 2006 [cited by applicant]
WO WO2006035282A2 · 2006 [cited by applicant]
WO WO2007007281A2 · 2007 [cited by applicant]
WO WO2007087276A1 · 2007 [cited by applicant]
WO WO2007100670A1 · 2007 [cited by applicant]
WO WO2007138431A2 · 2007 [cited by applicant]
WO WO2008065500A2 · 2008 [cited by applicant]
WO WO2009137308A1 · 2009 [cited by applicant]
WO WO2010067102A1 · 2010 [cited by applicant]
WO WO2011084796A2 · 2011 [cited by applicant]
WO WO2012047703A2 · 2012 [cited by applicant]
WO WO2012154731A1 · 2012 [cited by applicant]
WO WO2012170976A2 · 2012 [cited by applicant]
WO WO2013063549A1 · 2013 [cited by applicant]
WO WO2013103931A1 · 2013 [cited by applicant]
WO WO2013127269A1 · 2013 [cited by applicant]
WO WO2014035829A1 · 2014 [cited by applicant]
WO WO2014045031A1 · 2014 [cited by applicant]
WO WO2014055955A1 · 2014 [cited by applicant]
WO WO2014072261A1 · 2014 [cited by applicant]
WO WO2014093230A2 · 2014 [cited by applicant]
WO WO2015027204A1 · 2015 [cited by applicant]
WO WO2015027214A1 · 2015 [cited by applicant]
WO WO2015058163A2 · 2015 [cited by applicant]
WO WO2015061247A2 · 2015 [cited by applicant]
WO WO2015078374A1 · 2015 [cited by applicant]
WO WO2015094803A1 · 2015 [cited by applicant]
WO WO2015118342A1 · 2015 [cited by applicant]
WO WO2015119899A1 · 2015 [cited by applicant]
WO WO2016049165A1 · 2016 [cited by applicant]
WO WO2016147011A1 · 2016 [cited by applicant]
WO WO2016194831A1 · 2016 [cited by applicant]
WO WO2017001660A1 · 2017 [cited by applicant]
WO WO2017021728A1 · 2017 [cited by applicant]
WO WO2017021729A1 · 2017 [cited by applicant]
WO WO2017077292A1 · 2017 [cited by applicant]
WO WO2017079641A1 · 2017 [cited by applicant]
WO WO2017083867A1 · 2017 [cited by applicant]
WO WO2017143041A1 · 2017 [cited by applicant]
WO WO2018042362A1 · 2018 [cited by applicant]
WO WO2018093694A1 · 2018 [cited by applicant]
WO WO2018226150A1 · 2018 [cited by applicant]
WO WO2019014427A1 · 2019 [cited by applicant]
WO 2019032654A1 · 2019 [cited by applicant]
WO 2019079783A1 · 2019 [cited by applicant]
WO WO2019079410A1 · 2019 [cited by applicant]
WO WO2019089676A1 · 2019 [cited by applicant]
WO WO2019126559A1 · 2019 [cited by applicant]
WO WO2019152809A1 · 2019 [cited by applicant]
WO WO2019245890A1 · 2019 [cited by applicant]
WO 2021067696A1 · 2021 [cited by applicant]
WO 2021119254A1 · 2021 [cited by applicant]
WO 2021119265A1 · 2021 [cited by applicant]
WO 2021216949A1 · 2021 [cited by applicant]
WO 2021216951A1 · 2021 [cited by applicant]
WO WO2022036177A1 · 2022 [cited by applicant]
WO 2022109099A1 · 2022 [cited by applicant]
WO WO2022140499A1 · 2022 [cited by applicant]
WO 2022212819A1 · 2022 [cited by applicant]
WO 2022216655A1 · 2022 [cited by applicant]
WO 2022261427A1 · 2022 [cited by applicant]
U.S. Appl. No. 19/537,072, filed Feb. 11, 2026, Bender; Aaron M. [cited by examiner]
Brown, Bioisosteres in Medicinal Chemistry, 2012 (Year: 2012). [cited by examiner]
International Search Report and Written Opinion for Application No. PCT/US2021/064776 dated Apr. 25, 2022 (15 pages). [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2021/064776 dated Jun. 13, 2023 (6 pages). [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2022/051493 dated Feb. 3, 2023 (12 pages). [cited by applicant]
Moehle, M. S., et al. “Discovery of the first selective M4 muscarinic acetylcholine receptor antagonists with in vivo antiparkinsonian and antidystonic efficacy.” ACS Pharmacology & Translational Science 4.4 (2021): 130… [cited by applicant]
Anonymous, Aurora Product Guide (Undated), 1 page retrieved on Apr. 28, 15 from the Internet at http:///www.aurorafinechemicals.com/about.html. [cited by applicant]
Betz et al., “The Muscarinic Receptor Antagonist Tropicamide Suppresses Tremulous Jaw Movements in a Rodent Model of Parkinsonian Termor: Possible Role of M4 Receptors”, Psychopharmacology, 2007, pp. 347-359. [cited by applicant]
Calaf et al., Muscarinic Receptors Associated with Cancer, (Cancers 2022, 14, 2322) (Year: 2022) pp. 1-32. [cited by applicant]
CAS No. 1445085-77-7, RuPhos-Pd-G3 is (2-dicyclohexylphosphino-2′,6′-diisopropoxy-l, l ′-bipheny1)[2-(2′-amino-1, 1′-biphenyl)]palladium(II) methanesulfonate, 12 pages, Version 6.8 Revision date: Sep. 6, 2024, Print dat… [cited by applicant]
CAS No. 1470372-59-8, “BrettPhos-Pd-G3 is [(2-di-cyclohexylphosphino-3,6-dimethoxy-2′,4′, 6′- triisopropyl-1, 1 ′-biphenyl)-2-(2′-amino-l, l′-biphenyl)]palladium(II) methanesulfonate,” 10 pages, Version 6.7, Revision Da… [cited by applicant]
CAS Registry No. 2062273-71-4 (Jan. 31, 2017), 2061991-72-6 (Jan. 30, 2017), 2061991-39-5 (Jan. 30, 2017), 2061296-30-6 (Jan. 29, 2017), 2061296-12-4 (Jan. 29, 2017), 2061295-98-3 (Jan. 29, 2017), 2061123-91-7 (Jan. 29,… [cited by applicant]
CAS Registry No. 2164592-45-2 (entered Dec. 6, 2017), CAS Registration No. 2152087-70-0 (entered Nov. 30, 2017), CAS Registration No. 2148484-96-0 (entered Nov. 11, 2016), CAS Registration No. 2029853-92-5 (entered Nov.… [cited by applicant]
Cross and Klyne, “IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry”, Pure Appl. Chem., vol. 45, 1976, pp. 13-30. [cited by applicant]
Croy et al., “Characterization of PCS1055, A Novel Muscarinic M4 Receptor Antagonist”, European Journal of Pharmacology, vol. 782, 2016, pp. 70-76. [cited by applicant]
Cuevas, J. et al. M4 Muscarinic Receptor Activation Modulates Calcium Channel Currents in Rat Intracardiac Neurons. Journal of Neurophysiology, 1997, 78, 4, 1903-1912. [cited by applicant]
Database Registry, 2017, RN 2062273-71-4, 2061991-72-6, 2061991-39-5, 2061296-30-6, 2061296-12-4, 2061295-98-3, 2061123-91-7, 2061123-31-5, 2061123-14-4, 2059865-58-4, 2058995-92-7, 2058995-23-4, 2058986-81-3, 2058767-5… [cited by applicant]
Dencker et al., “Muscarinic Acetylcholine Receptor Subtypes As Potential Drug Targets for the Treatment of Schizophrenia, Drug Abuse, and Parkinson's Disease”, ACS Chemical Neuroscience, vol. 3, 2012, pp. 80-89. [cited by applicant]
Evans in “Principles of Radiopharmacology”, Colombett, L.G. editor, CRC Press, pp. 11-13 and 24 (1979). [cited by applicant]
Extended European Search Report for European Application No. 24202370.3 mailed Mar. 26, 2025, 8 pages. [cited by applicant]
Fahn, S. et al., “Antimuscarinic Drugs in the Treatment of Movement Disorders,” Prog Brain Res. 84:389-97 (1990). [cited by applicant]
Foster, Daniel J, et al. Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia. Neuropsychiatric Disease and Treatment 10:183-191 (2014). [cited by applicant]
Gomeza et al., “Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M4 muscarinic acetylcholine receptor knockout mice,” Proc. Natl. Acad. Sci. USA (1999) 10483-10488. [cited by applicant]
Hackam et al., “Translation of Research Evidence From Animals to Humans,” JAMA, 296(14): 1731-1732 (Nov. 2006). [cited by applicant]
Jeon et al., A Subpopulation of Neuronal M4 Muscarinic Acetylcholine Receptors Plays a Critical Role in Modulating Dopamine-Dependent Behaviors J. Neurosci. 2396-2405 (Feb. 10, 2010). [cited by applicant]
Jordan “Tamoxifen: A most Unlikely Pioneering Medicine” Nature Reviews: Drug Discovery (2003); 2:205-213. [cited by applicant]
Moehle MS, et al., “Cholinergic Projections to the Substantia Nigra Pars Reticulata Inhibit Dopamine Modulation of Basal Ganglia Through the M4 Muscarinic Receptor,” Neuron.96(6):1358-1372.e4 (Dec. 20, 2017). [cited by applicant]
PubChem CID 110134863, pp. 1-9. National Center for Biotechnology Information. PubChem Compound Summary for CID 110134863. Create Date: Jan. 18, 2016; 9 pages, [Retrieved online at https://pubchem.ncbi.nlm.nih.gov/compo… [cited by applicant]
PubChem CID 121247417, National Center for Biotechnology Information. PubChem Compound Summary for CID 121247417. https://pubchem.ncbi.nlm.nih.gov/compound/121247417. Create date Aug. 6, 2016, 9 pages. [cited by applicant]
Pubchem CID: 86299010, Create date: Dec. 31, 2014, pp. 1-12 [Retrieved online Dec. 11, 18 at https;//pubc hem.ncbi.nlm.nih.gov/com pound/862990010]. [cited by applicant]
Pubchem, CID62483681, Oct. 22, 2012, 10 pages [Retrieved online Jan. 7, 2025 at https;//pubc hem.ncbi.nlm.nih.gov/compound/62483681]. [cited by applicant]
PubChem-CID-43599258, Create Date: Jul. 21, 2009 (Jul. 21, 2009), 9 pages. [cited by applicant]
RN 1877193-30-0, entered into CA registry File on Mar. 1, 2016, supplied by Ukrorsyntez Ltd., 1 page. [cited by applicant]
RN 1877470-60-4, entered into CA registry File on Mar. 2, 2016, supplied by Ukrorsyntez Ltd., 1 page. [cited by applicant]
RN 2023174-15-2, entered into CA registry File on Nov. 2, 2016, supplied by Ukrorsyntez Ltd., 1 page. [cited by applicant]
RN 2060739-31-1, entered into CA registry File on Jan. 29, 2017, supplied by Aurora Fine Chemicals, 1 page. [cited by applicant]
RN 2062200-26-2, entered into CA registry File on Jan. 31, 2017, supplied by Aurora Fine Chemicals, 1 page. [cited by applicant]
Tsuji, T. et al. “Discovery of novel pyridazine derivatives as glucose transporter type 4 (GLUT4) translocation activators.” Bioorganic & Medicinal Chemistry Letters 29.14 (2019): 1785-1790. [cited by applicant]
Uorsy Product Guide (2021), 6 pages retrieved from the Internet at http://uorsy.com on Jul. 29, 2021. [cited by applicant]
Westhuizen, E. et al. Fine Tuning Muscarinic Acetylcholine Receptor Signaling Through Allostery and Bias Front Pharmacol. 2021, 11:606656. [cited by applicant]
Wood, M. R., et al. “Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5, 6-dimethyl-4-(piperidin-1-yl) thieno [2, 3-d] pyrimidine core.” Bioorganic & medicinal chemistry letters 26… [cited by applicant]
Zak et al., “Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors”, Journal of Medicinal Chemistry, vol. 59, 2016, pp. 8345-8368. [cited by applicant]
Zhao et al., “Design of a New Histamine H3 Receptor Antagonist Chemotype: (3aR, 6aR)-5-Alkyl-1-aryl-pctahydropyrrolo[3,4,-b]pyrroles, Synthesis and Structure—Activity Relationships”, Journal of Medicinal Chemistry, vol.… [cited by applicant]
Zheng Y, et al., The Use of Spirocyclic Scaffolds in Drug Discovery. Bioorg Med Chem Lett. Aug. 15, 2014;24(16):3673-3682. doi: 10.1016/j.bmcl.2014.06.081. Epub Jul. 5, 2014. PMID: 25052427. [cited by applicant]
Zhu, Wei et al. Recent advances in the trifluoromethylation methodology and new CF3-Containing drugs. Journal of Fluorine Chemistry 167 (2014) 37-54. (2014). [cited by applicant]
Bunnett.J.F., et al., “Names for Hydrogen Atoms, lons, and Groups, and for Reactions Involving them”, International Union of Pure and Applied Chemistry., Pure & Appl. Chem., vol. 60, No. 7, pp. 1115-1116 (Jan. 1988). [cited by applicant]
Cas Registry No. 2307718-06-3, “CN Methanesulfonamide, N-[4-[(3aR,6aS)-5-[[6-(2-chloro-5-fluorophenyl)-3-pyri dazinyl]amino]hexahydrocyclopenta[c]pyrrol-2(1H)-yl]methyl]phenyl]-, rel- (CA Index Name),” [cas.org] (which … [cited by applicant]
Hildebrand M., et al., “Selective Inhibition of Cav3.3 T-type Calcium Channels by Gq/11-coupled Muscarinic Acetylcholine Receptors,” Journal of Biological Chemistry, Dec. 26, 2006, vol. 282(29), pp. 21043-21055. [cited by applicant]
Pemberton, K., et al., “Modulation of Low-threshold T-type Calcium Channels by the Five Muscarinic Receptor Subtypes in Nih T3 Cells” Eur J Physiol, vol. 440, pp. 452-461 (May 3, 2000). [cited by applicant]